Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding

PHASE4TerminatedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

June 28, 2018

Study Completion Date

July 6, 2020

Conditions
Adenoma
Interventions
DRUG

octreotide

Octreotide 100mg subcutaneous every 8 hours for 5 days

OTHER

No Octreotide

No drug

Trial Locations (1)

32803

Florida Hospital, Orlando

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AdventHealth

OTHER